等待开盘 09-18 09:30:00 美东时间
+0.326
+1.23%
TradingKey - Merck stock surged after its personalized mRNA cancer therapy met both Phase 3 melanoma endpoints. Strong Q2 sales and pipeline growth support MRK’s outlook.
08-20 02:27
Merck (MRK) was up around 5% premarket on Thursday after it beat top- and bottom-line estimates for Q1 and issued a narrowed outlook for 2026. The Rahway, New Jersey–based company adjusted its guidanc...
04-30 18:59
https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
04-21 23:50